- By ICR Secretariat
- Posted Wednesday, April 5, 2023
GSK plays defense after California judge approves plaintiff's expert testimony in high-stakes Zantac trial
https://www.fiercepharma.com/pharma/gsk-plays-defense-after-california-judge-approves-plaintiffs-expert-testimony-1st-state
After eluding thousands of federal lawsuits because a U.S. district judge rejected the science behind plaintiffs’ claims, GSK will be forced to defend itself against allegations that its fallen heartburn med Zantac causes cancer in state court this summer.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- Future of Intercept’s NASH drug in doubt after FDA panel rejection 30/05/2023 03:56 PM
- 'The Top Line': 2023's biopharma layoffs, plus this week's headlines 30/05/2023 03:55 PM
- How the digital front door benefits clinical trial patients, clinicians and sponsors 30/05/2023 03:53 PM
Useful Links
Contact Us
Suite 11a, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org